Showing results (21-30 of 46) with videos related to
Sort By:
Pageof 5
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 2, 2017
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque PsoriasisHema N Viswanathan, Alex Mutebi, Cassandra E Milmont, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2007
Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humansBindhu Karanam, Maria Madeira, Scott Bradley, et al.Plos One|September 9, 2022
COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccineGregory Huhn, Josh Poorbaugh, Lin Zhang, et al.Journal of Clinical Pharmacology|May 21, 2010
Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairmentYing-Hong Wang, Fang Liu, Julie Ann Mabalot Luk, et al.Biomarkers in Medicine|August 25, 2012
Quantifying monocyte infiltration in response to intradermal tetanus toxoid injectionJoanna Z Peng, David E Gutstein, Lisa Beck, et al.Journal of the American Academy of Dermatology|May 22, 2016
Clinical meaningfulness of complete skin clearance in psoriasisBruce Strober, Kim A Papp, Mark Lebwohl, et al.Nature Communications|October 25, 2024
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I Silverberg, David Rosmarin, Raj Chovatiya, et al.Science Translational Medicine|June 9, 2022
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccinationRobert J Benschop, Jay L Tuttle, Lin Zhang, et al.Nature Communications|May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical studyAnja Koester, Derrick R Witcher, Mark Lee, et al.Clinical Pharmacology and Therapeutics|August 29, 2021
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19Peter Chen, Gourab Datta, Ying Grace Li, et al.Pageof 5